Fasting C-peptide Levels as Predictor Marker for Type1 Diabetes Mellitus among Diabetic Children at Khartoum State
Abstract
Background: Diabetes Mellitus (DM) is a major health problem worldwide. It can lead to life-threatening complication. So C-peptide (Cp) serves as a surrogate of pancreatic beta-cell reserve which can predict complication.
Objectives: To evaluate the clinical significance of basal Cp as a predictor of type 1diabetes (T1D) and investigate the association of serum C-peptide level and BMI, HbA1c, age ,age of onset and duration of disease in children with diabetes mellitus .
Methods: It was a descriptive cross sectional study conducted at Mohammed Elamin Hamid Pediatric Hospital during the period from November to April 2018. In this study 40 blood samples were collected and analyzed colorimetrically using ELISA technique, 40 samples (18 boys and 22 girls) from children with diabetes mellitus conducted in it. Statistical analysis: all the data was analyzed using (SPSS) version 21. The results were expressed as Mean±SD and percentage. One sample t-test and personal correlation test used to correlate between C-peptide and age, age of onset, duration of disease, HbA1c and BMI at p-value of < 0.05 considered as significant.
Results: It demonstrated that C-peptide was significantly decreased in diabetic patients compared to the mean of normal value (0.45±0.52, 1.55), (p value = 0.001), While HbA1C was significantly increased in diabetic patients compared to the mean of normal value (10.1± 2.5, 5.25). Also we found that C-peptide was weakly negative insignificant correlated with age, age of onset and HbA1C (R = -0.016, -0.016 and -0.046 respectively), (p value = 0.9, 0.9 and 0.7 respectively), while weakly positive insignificant correlated with BMI (R = 0.021), (p value = 0.8).
Conclusion: The study has concluded that the children with diabetes mellitus have significant decrease in C-peptide level and significant increase in HbA1c level in both male and female, compared to the reference value.
References
2- Hendriksen C, Faber OK, Dreier J, Binder C. 1977 Prevalence of residual ~-cell function in insulintreated diabetics evaluated by the plasma C-peptide response to intravenous glucagon. Diabetologia; 13: 615-9
3- Bell DSH, Ovalle F, 2004. The role of C-peptide levels in
screening for latent autoimmune diabetes in adults Am J Ther.;11:308–11.
4- Arikan E, Sabuncu T, Ozer EM, Hatemi H. The
clinical characteristics of latent autoimmune diabetes in adults and its relation with chronic complications in metabolically poor controlled Turkish
patients with type 2 diabetes mellitus. J Diabetes
Complications. 2005;19:254–8.
5- Kumar S, Subhakumari KN. 2016. Role of anti-GAD,
anti-IA2 antibodies and C-peptide in differentiating latent autoimmune diabetes in adults from type 2
diabetes mellitus.;36:313–9.
6- Madsbad S, Faber OK, Binder C, McNair P, Christiansen C, Transbøl I. 1978 Prevalence of residual betacell function in insulin-dependent diabetics in
relation to age at onset and duration of diabetes.
Diabetes.;27(Suppl1) :262–4.
7- Wang L, Lovejoy NF, Faustman DL. 2012 Persistence of
prolonged C-peptide production in type 1 diabetes
as measured with an ultrasensitive C-peptide assay.
Diabetes Care.;35:465–70.
8- Greenbaum CJ, Beam CA, Boulware D, et al, 2012. Fall in
C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite type 1 diabetes TrialNet data. Diabetes.;61: 2066–73.
9- Davis AK, DuBose SN, Haller MJ, et al. 2015. Prevalence of
detectable C-peptide according to age at diagnosis
and duration of type 1 diabetes. Diabetes Care 38:476–81.
10- Hattersley A, Bruining J, Shield Njolstad P, Donaghue K, 2006 International Society for Pediatric and Adolescent Diabetes. ISPAD clinical practice consensus guidelines 2006–2007. The diagnosis and
management of monogenic diabetes in children.
Pediatr Diabetes 7:352–60.
